Opzelura is the brand name for topical ruxolitinib (1.5% cream), a JAK1/JAK2 inhibitor applied to the skin. It has been studied mainly for two conditions:
- Atopic dermatitis (AD) in adults and adolescents
- Nonsegmental vitiligo in adults (and studies in older children)
Key clinical trials
- Atopic dermatitis
- Phases: TRuE-AD1 and TRuE-AD2 (Phase 3)
- Design: randomized, double-blind, vehicle-controlled
- What they looked at: skin clearance (IGA 0/1) and skin inflammation (EASI), plus itch reduction
- Takeaway: Opzelura 1.5% cream showed superior improvement versus vehicle by about 8 weeks, with meaningful reductions in itch and skin severity reported in participants with AD.
- Vitiligo (nonsegmental)
- Phases: pivotal Phase 3 studies often summarized under the Opzelura vitiligo program
- Design: randomized, controlled trials
- What they looked at: repigmentation outcomes and global assessments of vitiligo
- Takeaway: trials demonstrated treatment-associated repigmentation in facial and other areas compared with control/placebo.
Safety and use
- Common adverse events: local skin reactions (like application-site dermatitis or irritation) and mild infections (e.g., cold symptoms) are reported more often than with vehicle.
- Serious risks: as with JAK inhibitors, there are warnings about infections, potential effects on the immune system, and theoretical risks of thrombosis or malignancy, though topical exposure is much lower than with systemic JAK inhibitors. Use caution in pregnancy and in people with active infections.
- Dosing: typically applied twice daily to affected skin areas. Do not apply to broken or irritated skin and avoid contact with eyes, mouth, or mucous membranes.
If you want more detail, I can pull exact trial names, NCT numbers, enrollment, and the specific endpoints/results (with numbers) from the published reports. I can also look up the current regulatory status by region (FDA, EMA, etc.) and summarize ongoing or future trials.
Would you like me to fetch the trial IDs and give a side-by-side summary (endpoints, results, and populations) or are you looking for something else (e.g., mechanism, who should consider Opzelura, or dosing instructions)?